148 related articles for article (PubMed ID: 9435867)
21. A novel bispecific antihuman CD40/CD86 fusion protein with t-cell tolerizing potential.
Koenen HJ; den Hartog MT; Heerkens S; Fasse E; Ortiz-Buijsse A; van Neerven RJ; Simons PJ; Joosten I; Boon L
Transplantation; 2004 Nov; 78(10):1429-38. PubMed ID: 15599306
[TBL] [Abstract][Full Text] [Related]
22. The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3.
Stel AJ; Kroesen BJ; Jacobs S; Groen H; de Leij LF; Kluin-Nelemans HC; Withoff S
J Immunol; 2004 Nov; 173(10):6009-16. PubMed ID: 15528335
[TBL] [Abstract][Full Text] [Related]
23. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
Demanet C; Brissinck J; De Jonge J; Thielemans K
J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells.
Daniel PT; Kroidl A; Kopp J; Sturm I; Moldenhauer G; Dörken B; Pezzutto A
Blood; 1998 Dec; 92(12):4750-7. PubMed ID: 9845541
[TBL] [Abstract][Full Text] [Related]
25. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.
Klein SC; Boer LH; de Weger RA; de Gast GC; Bast EJ
Scand J Immunol; 1997 Nov; 46(5):452-8. PubMed ID: 9393627
[TBL] [Abstract][Full Text] [Related]
26. Bispecific antibody fragments with CD20 X CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma.
Brandl M; Grosse-Hovest L; Holler E; Kolb HJ; Jung G
Exp Hematol; 1999 Aug; 27(8):1264-70. PubMed ID: 10428503
[TBL] [Abstract][Full Text] [Related]
27. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
Löffler A; Kufer P; Lutterbüse R; Zettl F; Daniel PT; Schwenkenbecher JM; Riethmüller G; Dörken B; Bargou RC
Blood; 2000 Mar; 95(6):2098-103. PubMed ID: 10706880
[TBL] [Abstract][Full Text] [Related]
28. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
Haagen IA
Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
[TBL] [Abstract][Full Text] [Related]
29. Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction.
Kwekkeboom J; de Rijk D; Kasran A; Barcy S; de Groot C; de Boer M
Eur J Immunol; 1994 Mar; 24(3):508-17. PubMed ID: 7510232
[TBL] [Abstract][Full Text] [Related]
30. Interaction of B cells with activated T cells reduces the threshold for CD40-mediated B cell activation.
Klaus GG; Holman M; Johnson-Léger C; Christenson JR; Kehry MR
Int Immunol; 1999 Jan; 11(1):71-9. PubMed ID: 10050675
[TBL] [Abstract][Full Text] [Related]
31. CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity.
Vonderheide RH; Butler MO; Liu JF; Battle TE; Hirano N; Gribben JG; Frank DA; Schultze JL; Nadler LM
Int J Oncol; 2001 Oct; 19(4):791-8. PubMed ID: 11562757
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model.
Panjideh H; Müller G; Koch M; Wilde F; Scheu S; Moldenhauer G; Lipp M
Int J Cancer; 2014 Dec; 135(11):2623-32. PubMed ID: 24729415
[TBL] [Abstract][Full Text] [Related]
33. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.
Reusch U; Le Gall F; Hensel M; Moldenhauer G; Ho AD; Little M; Kipriyanov SM
Int J Cancer; 2004 Nov; 112(3):509-18. PubMed ID: 15382079
[TBL] [Abstract][Full Text] [Related]
34. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16.
Pörtner LM; Schönberg K; Hejazi M; Brünnert D; Neumann F; Galonska L; Reusch U; Little M; Haas R; Uhrberg M
Cancer Immunol Immunother; 2012 Oct; 61(10):1869-75. PubMed ID: 22976535
[TBL] [Abstract][Full Text] [Related]
35. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.
Kufer P; Mack M; Gruber R; Lutterbüse R; Zettl F; Riethmüller G
Cancer Immunol Immunother; 1997; 45(3-4):193-7. PubMed ID: 9435872
[TBL] [Abstract][Full Text] [Related]
36. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
37. Bispecific antibody treatment of murine B cell lymphoma.
De Jonge J; Heirman C; De Veerman M; Van Meirvenne S; Demanet C; Brissinck J; Thielemens K
Cancer Immunol Immunother; 1997; 45(3-4):162-5. PubMed ID: 9435864
[TBL] [Abstract][Full Text] [Related]
38. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.
Xiong D; Xu Y; Liu H; Peng H; Shao X; Lai Z; Fan D; Yang M; Han J; Xie Y; Yang C; Zhu Z
Cancer Lett; 2002 Mar; 177(1):29-39. PubMed ID: 11809528
[TBL] [Abstract][Full Text] [Related]
39. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma.
Moore PA; Zhang W; Rainey GJ; Burke S; Li H; Huang L; Gorlatov S; Veri MC; Aggarwal S; Yang Y; Shah K; Jin L; Zhang S; He L; Zhang T; Ciccarone V; Koenig S; Bonvini E; Johnson S
Blood; 2011 Apr; 117(17):4542-51. PubMed ID: 21300981
[TBL] [Abstract][Full Text] [Related]
40. T cell activation and retargeting using staphylococcal enterotoxin B and bispecific antibody: an effective in vivo antitumor strategy.
Porter LE; Nelson H; Ethem Gecim I; Rice DC; Thibault C; Chapoval AI
Cancer Immunol Immunother; 1997; 45(3-4):180-3. PubMed ID: 9435868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
